Simple Reset (SR-17)

What the brand says

Simple Reset has a real marketing footprint, so unlike most of this wave there are specific claims to look at. In the brand’s own words it’s a “transition and tolerance reset product built around SR-17018”, for people who want to lower tolerance, return to baseline, or step away from heavier daily use. The format is chewable tablets at 50mg each — ten to a 500mg bottle, twenty to a 1000mg bottle. The brand also states the product contains no detectable 7-hydroxymitragynine or other kratom alkaloids, and that it has passed residual solvent screening. Those are Simple Reset’s statements about its own product, not ours.

The kratom-free claim is almost certainly accurate, and it’s also where the framing gets slippery. SR-17018 isn’t a kratom alkaloid — it’s a synthetic mu-opioid agonist built at Scripps Research Institute — so of course a product formulated around it contains no leaf alkaloids. Kratom-free describes what isn’t in the tablet. It says nothing about what is.

What the public record says

The DEA placed SR-17018 — under its chemical name, 5,6-dichloro desmethylchlorphine — into Schedule I under a temporary scheduling order effective August 27, 2026, running through August 2028. Scheduling attaches to the molecule, which means it reaches every product formulated around it, whatever the brand name or the format. We aren’t making a claim about any particular seller here — only about the status of the active ingredient, which is a matter of public record.

On the reset claim itself: there are no completed human clinical trials of this compound, for tolerance or for anything else. The idea comes from rodent work, and the headline safety finding — that it avoids respiratory depression — came from studies dosing mice by injection, while oral dosing does produce significant respiratory depression in mice. The full breakdown is on our SR-17018 page, along with the pending legal challenge to the scheduling, which is a genuine open question worth knowing about.

Why this keeps happening

This is the third version of the same story in six months. Concentrated 7-OH was federally scheduled on August 5, 2026, which took Numbz, 7-OHMZ and the Dozo combo tabs off the market. A wave of cat’s-claw tablets followed and is already drawing poison-control alerts and a state attorney general’s investigation. SR-17018 was scheduled three weeks after 7-OH. The pattern is consistent enough to plan around: a novel molecule arrives dressed in wellness language, sells hard for a few months, and gets scheduled — and the product sold as the way off the last one becomes the next one.